| __timestamp | Grifols, S.A. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 504755000 |
| Thursday, January 1, 2015 | 736435000 | 838526000 |
| Friday, January 1, 2016 | 775266000 | 1177697000 |
| Sunday, January 1, 2017 | 860348000 | 1320433000 |
| Monday, January 1, 2018 | 814775000 | 1556200000 |
| Tuesday, January 1, 2019 | 942821000 | 1834800000 |
| Wednesday, January 1, 2020 | 985616000 | 1346000000 |
| Friday, January 1, 2021 | 1061508000 | 1824900000 |
| Saturday, January 1, 2022 | 1190423000 | 2115900000 |
| Sunday, January 1, 2023 | 1254234000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Grifols, S.A. have demonstrated contrasting strategies in optimizing these costs. From 2014 to 2023, Regeneron has seen a significant increase in SG&A expenses, rising by over 420%, from approximately $505 million to $2.63 billion. In contrast, Grifols has managed a more modest increase of around 90%, from $661 million to $1.25 billion.
This divergence highlights Regeneron's aggressive expansion and investment in administrative capabilities, while Grifols appears to focus on cost efficiency. As the pharmaceutical landscape evolves, these strategies will play a pivotal role in shaping each company's financial health and market position. Investors and industry analysts should closely monitor these trends to gauge future performance.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Grifols, S.A.
Revenue Insights: Regeneron Pharmaceuticals, Inc. and Grifols, S.A. Performance Compared
Regeneron Pharmaceuticals, Inc. or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Incyte Corporation or Grifols, S.A.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Insmed Incorporated vs Grifols, S.A.
Dr. Reddy's Laboratories Limited vs Grifols, S.A.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and PTC Therapeutics, Inc.